




# THE MYELOMA MOMENT: BCMA & THE CAR-T REVOLUTION

Multiple Myeloma, once a cycle of relapses, redefined by BCMA-targeted CAR-T. Therapies moving to earlier lines, with new sequential strategies to beat resistance.

## THE BCMA BREAKTHROUGH



- Achieved a 97% overall response rate in triple-class refractory myeloma patients.




- Established the field with a 73% response rate in highly pre-treated populations.

## Moving to Earlier Lines of Care


**FDA approval now includes second-line use based on a 74% reduction in progression risk.**

## FUTURE-PROOFING AGAINST RESISTANCE



**The Challenge of Antigen Escape:**  
Relapse often occurs when myeloma cells stop expressing BCMA to evade the CAR-T.

## Sequential Targeting Strategy



**GPRC5D:**  
The Next Major Target

Showing 70%+ response rates even in patients who previously failed BCMA CAR-T.

